Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, United States; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States; Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA, United States.
Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Diabetes Res Clin Pract. 2023 Mar;197:110572. doi: 10.1016/j.diabres.2023.110572. Epub 2023 Feb 11.
Recent USPSTF and ADA guidelines expanded criteria of whom to test to identify prediabetes and diabetes. We described which Americans are eligible and report receiving glucose testing by USPSTF 2015 and 2021 as well as ADA 2003 and 2022 recommendations, and performance of each guideline.
We analyzed cross-sectional data from 6,007 non-pregnant U.S. adults without diagnosed diabetes in the 2013-2018 National Health and Nutrition Examination Surveys. We reported proportions of adults who met each guideline's criteria for glucose testing and reported receiving glucose testing in the past three years, overall and by key population subgroups,. Defining prediabetes (FPG 100-125 mg/dL and/or HbA1c 5.7-6.4 %) or previously undiagnosed diabetes (FPG ≥ 126 mg/dL and/or HbA1c ≥ 6.5 %), we assessed sensitivity and specificity.
During 2013-2018, 76.7 million, 90.4 million, 157.7 million, and 169.5 million US adults met eligibility for glucose testing by USPSTF 2015, 2021, and ADA 2003 and 2022 guidelines, respectively. On average, 52 % of adults reported receiving glucose testing within the past 3 years. Likelihood of receiving glucose testing was lower among younger adults, men, Hispanic adults, those with less than high school completion, those living in poverty, and those without health insurance or a usual place of care than their respective counterparts. ADA recommendations were most sensitive (range: 91.0 % to 100.0 %) and least specific (range: 18.3 % to 35.3 %); USPSTF recommendations exhibited lower sensitivity (51.9 % to 66.6 %), but higher specificity (56.6 % to 74.5 %).
An additional 12-14 million US adults are eligible for diabetes screening. USPSTF 2021 criteria provide balanced sensitivity and specificity while ADA 2022 criteria maximize sensitivity. Glucose testing does not align with guidelines and disparities remain.
最近 USPSTF 和 ADA 指南扩大了筛查范围,以确定糖尿病前期和糖尿病。我们描述了哪些美国人符合条件,并根据 USPSTF 2015 年和 2021 年以及 ADA 2003 年和 2022 年的建议报告了接受葡萄糖检测的情况,以及每个指南的执行情况。
我们分析了 2013-2018 年全国健康与营养调查中 6007 名无糖尿病诊断的非妊娠美国成年人的横断面数据。我们报告了符合每个指南葡萄糖检测标准并在过去三年中报告接受葡萄糖检测的成年人比例,总体以及按关键人群亚组报告。通过定义糖尿病前期(FPG 100-125mg/dL 和/或 HbA1c 5.7-6.4%)或以前未诊断的糖尿病(FPG≥126mg/dL 和/或 HbA1c≥6.5%),我们评估了敏感性和特异性。
在 2013-2018 年期间,USPSTF 2015 年、2021 年以及 ADA 2003 年和 2022 年指南分别有 7670 万、9040 万、1.577 亿和 1.695 亿美国成年人符合葡萄糖检测的资格。平均而言,52%的成年人在过去 3 年内接受过葡萄糖检测。与同龄人相比,年轻成年人、男性、西班牙裔成年人、未完成高中学业的成年人、生活在贫困中的成年人以及没有医疗保险或常规医疗保健的成年人接受葡萄糖检测的可能性较低。ADA 建议的敏感性最高(范围:91.0%至 100.0%),特异性最低(范围:18.3%至 35.3%);USPSTF 建议的敏感性较低(51.9%至 66.6%),但特异性较高(56.6%至 74.5%)。
美国另有 1200 万至 1400 万成年人符合糖尿病筛查条件。USPSTF 2021 年的标准提供了平衡的敏感性和特异性,而 ADA 2022 年的标准最大限度地提高了敏感性。葡萄糖检测与指南不一致,差异仍然存在。